PDCD1 and head and neck squamous cell carcinoma: The neoadjuvant pembrolizumab plus docetaxel and cisplatin showed encouraging efficacy, with a high ORR of 87.8%, further supporting the evidence with anti-PD-1 therapy for treatment of HNSCC (16, 17).